Assessment and Treatment of Severe Asthma, According to Inflammatory Phenotypes, in Patients without a Response to Core Multidisciplinary Management. Eligibility for omalizumab includes an IgE level of at least 30 IU per milliliter and evidence of reactivity to at least one perennial aeroallergen. #Management #PCC #Asthma #Severe #Algorithm #Phenotypes #NEJM
